Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.Alnylam Pharmaceuticals (ALNY 0.17%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of$0.60 per share. Revenue of $593.2 million also outpaced the expected$584 million. This quarter's str ...